74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Legend Biotech Corp ADR
Closed
SectorHealthcare
33.29 5.75
Overview
Share price change
24h
Min
30.96
Max
33.51
Income | 161M 41M |
|---|---|
Sales | 26M 187M |
EPS | 0.14 |
Profit margin | 21.719 |
Employees | 2,600 |
EBITDA | 162M 52M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +164.47% upside |
Next Earnings | 12 May 2025 |
|---|
Market Cap | -30M 6.4B |
|---|---|
Previous open | 27.54 |
Previous close | 33.29 |
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Legend Biotech Corp ADR Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Legend Biotech Corp ADR Forecast
Price Target
By TipRanks
164.47% upside
12 Months Forecast
Average 83.36 USD 164.47%
High 95 USD
Low 62 USD
Based on 15 Wall Street analysts offering 12 month price targets forLegend Biotech Corp ADR - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Legend Biotech Corp ADR
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.
